home / stock / indp / indp news

INDP News and Press, Indaptus Therapeutics Inc. From 05/01/23

Stock Information
Company Name: Indaptus Therapeutics Inc.
Stock Symbol: INDP
Market: NASDAQ
Website: indaptusrx.com/
Menu
INDP INDP Quote INDP Short INDP News INDP Articles INDP Message Board
Get INDP Alerts

News, Short Squeeze, Breakout and More Instantly...
INDP - Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the Company’s Chief Sc...
INDP - Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCa...

INDP - UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at t...

INDP - Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at t...
INDP - Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has received a patent allowance on Application #1120150158323 from the National ...

INDP - Indaptus Therapeutics to Present at the Investor Summit Conference

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it will participate at the Investor Summit Conference being held virtually on ...

INDP - Indaptus Therapeutics GAAP EPS of -$1.73 beats by $0.21

2023-03-17 08:18:00 ET Indaptus Therapeutics press release ( NASDAQ: INDP ): FY GAAP EPS of -$1.73 beats by $0.21 . As of December 31, 2022, the company had cash and cash equivalents and marketable securities of approximately $26.4 million. As of December 31, 2021,...
INDP - Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a corporate update. “With t...

INDP - Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that the American Association f...

INDP - Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that Atlanta, Ga.-based Emory W...
Previous 10 Next 10